Firm Client Boustead Securities Completes Kairos Pharma Initial Public Offering

Olshan acted as counsel to Boustead Securities, LLC, as lead managing underwriter, in Kairos Pharma, Ltd.’s initial public offering of 1,550,000 shares of common stock for gross proceeds of $6.2 million. Kairos Pharma is a clinical stage biopharmaceutical company developing cancer therapeutics designed to reverse cancer drug resistance and immune suppression. Kairos Pharma has granted the underwriters an over-allotment option to purchase an additional 232,500 shares. Kairos Pharma’s common stock began trading on the NYSE American on September 16, 2024 under the symbol “KAPA.” EF Hutton LLC acted as co-managing underwriter for the offering. The Olshan team was led by corporate partner Spencer G. Feldman and corporate associate Dakota J. Forsyth.